Cargando…

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()

BACKGROUND: Ipilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment neutrophil to lymphocyte ratio (NLR) has been associated with outcome in IPI-treated patients, but has not been studied during treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cassidy, Michael R., Wolchok, Rachel E., Zheng, Junting, Panageas, Katherine S., Wolchok, Jedd D., Coit, Daniel, Postow, Michael A., Ariyan, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405176/ https://www.ncbi.nlm.nih.gov/pubmed/28356222 http://dx.doi.org/10.1016/j.ebiom.2017.03.029

Ejemplares similares

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
por: Tokunaga, Akihiro, et al.
Publicado: (2019)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
por: Yuan, Jianda, et al.
Publicado: (2013)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Iinuma, Koji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i0vtq3j2ur8addmo8qtd4o4es8